Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China · Delayed Price · Currency is CNY 89.69
+2.69 (3.09%)
Jun 18, 2026, 3:00 PM CST
SHA:688266 Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, SHA:688266 stock has a consensus rating of "Strong Buy" and an average price target of ¥148.04. The average 1-year stock price forecast is 65.06% higher than the current stock price, while the lowest is ¥135.00 (+50.52%) and the highest is ¥161.08 (+79.60%).
Price Target: ¥148.04 (+65.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SHA:688266 stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 5 | 4 |
Financial Forecast
Revenue This Year
1.80B
from 810.48M
Increased by 121.53%
Revenue Next Year
2.23B
from 1.80B
Increased by 24.37%
EPS This Year
-0.07
from -0.75
EPS Next Year
n/a
from -0.07
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.9B | ||
| Avg | 1.8B | ||
| Low | 1.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 129.6% | ||
| Avg | 121.5% | ||
| Low | 113.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.07 | ||
| Avg | -0.07 | ||
| Low | -0.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |